Thursday 16 October, 2025
Objectives Quantitative system pharmacology (QSP) models are widely used in drug discovery and development to understand the complex interactions between…
Read morePoster: Methodology - New Modelling Approaches
Inter-species and in vitro-in vivo scaling for quantitative modeling of whole-body drug pharmacokinetics in patients: Application to the anticancer drug oxaliplatin
Thursday 16 October, 2025
Objectives: We designed a physiologically based pharmacokinetic (PBPK)model of the anticancer drug oxaliplatin, and developed a scaling methodology that shows…
Read moreBridging the gap between two-stage and joint models: The case of tumor growth inhibition and overall survival models
Thursday 16 October, 2025
Objectives: Many clinical trials generate both longitudinal biomarkers and time-to-event data. We might be interested in their relationship, as in the…
Read moreModelling selective cell targeting through avidity to inform bispecific antibody discovery and development
Thursday 16 October, 2025
Objectives: Avidity is the phenomena referring to an increasing probability of a bivalent binder to bind a second target after…
Read moreDeveloping a PBPK/PD/Tox Modelling Framework for NANOBODY® Drug Conjugates
Thursday 16 October, 2025
Introduction: Sanofi R&D, Ghent, Belgium has initiated a project towards the rational design of NANOBODY®-Drug Conjugates (NDCs). NDCs are molecular…
Read moreAn Artificial Intelligence Framework for Optimal Drug Design
Thursday 16 October, 2025
Objectives: To develop an end-to-end in silico framework for optimizing the exposure, safety, and efficacy of drugs. To provide a proof-of-concept…
Read moreBeyond the Liver; In Silico Screening for Tissue-Specific Oligonucleotide Delivery Receptors
Thursday 16 October, 2025
Introduction: Oligonucleotide therapeutics represent a promising novel treatment modality that has gained wide traction in the past few years due…
Read moreOpen-science solutions enabled within a digital research environment to support MIDD (Model Informed Drug Development) and precision dosing
Thursday 16 October, 2025
Objectives: We propose to enhance the outreach and reliability of current open-science solutions supporting MIDD and precision dosing as part of…
Read morestormTB: SimulaTOR of a murine Minimal-pbpk model for anti-TB drugs
Thursday 16 October, 2025
Introduction/Objectives: In 2022 Tuberculosis (TB) was the second cause of death due to a single infectious agent after COVID-19 and…
Read moreRevising the assessment of bioequivalence in the light of finite absorption time (FAT) concept: The axitinib case
Thursday 16 October, 2025
Objectives: Pharmacokinetics since its inception (1) in 1953 has been built on the notion of an infinite time for oral…
Read more